imagen laboratorio

Currently at SRB




Bonos de Innovación GAIN



Innovation Plan





Debiopharm Extends SunRock Biopharma Partnership for Antibody Drug Conjugates Targeting HER3 in EGFR Mutated Cancers

Debiopharm (, a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today secured an…

Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-Treat Cancers

September 21, 2023 Debiopharm to boost its ADC oncology pipeline through multi-asset partnership with SunRock’s antibody portfolio integrating Multilink™ & AbYlink™…

Research activity starts in Santiago at the Sionlla Biopolo with the installation of SunRock and Zinpro

The company from Santiago de Compostela is searching for antibodies against cancer, while the multinational is working on animal welfare. The…

SunRock Biopharma and VHIO are beneficiaries of a project funded with 1.7 million euros for the development of new antibodies for the treatment of solid tumors

The initiative aims to advance the development of new therapeutic options for breast cancer, colorectal cancer, and head and neck cancer….

SunRock Biopharma and IDIS secure 1.8 million euros in funding for the IMPANC project.

This initiative aims to advance the study of a new and effective therapeutic alternative that improves the lives of pancreatic cancer…

SunRock Biopharma receives the Bioga Award as a Competitive BioCompany

The company’s experience and trajectory in the development of cancer treatments have made SunRock worthy of this recognition. The Business Technology…

Ellipses Pharma and SunRock Biopharma enter into a licensing agreement for a first-in-class bifunctional HER3:TRAIL fusion protein

Ellipses Pharma granted exclusive global rights to develop and commercialise SRB22, in solid tumours   LONDON and SANTIAGO DE COMPOSTELA, Spain,…


Axencia Galega de Innovación